Skip to main content
OpenTrials
Completed

NCT Number: NCT00626795

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner according to age groups starting with the oldest age group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Impetigo Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Secondarily Infected Traumatic Lesions Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Staphylococcal Infections Staphylococcal Skin Infections Streptococcal Infections

Age range

2 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Division of Dermatology, Groote Schuur Hospital, G23, Cape Town, Western Cape, South Africa

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed and dated informed consent from patient and/or legally acceptable representative has been obtained
  • Outpatients of any sex or ethnic origin
  • Patients >= 2 years of age (depending on study step)
  • Patients must be suffering from primary bullous/non-bullous impetigo or SITL

Exclusion criteria

  • Presence of skin diseases at or near the investigational area
  • Immunosuppressed state or other serious systemic disease
  • Signs and/or symptoms of systemic infection
  • Presence of skin infection/disorder not amenable to topical antibacterial treatment only
  • Presence of secondarily-infected animal/human bite
  • Presence of secondarily infected burnwound
  • Topical or systemic use of medicinal or other products before or during the study which in the investigators opinion could confound the evaluation of the effect of the study drugs
  • Known or suspected hypersensitivity to TD1414 or any of the excipients in the TD1414 2% cream
  • Known or suspected hypersensitivity to mupirocin or any of the excipients in the Bactroban® (mupirocin) 2% cream
  • Participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomisation
  • Patients previously enrolled/randomised in this study
  • Abnormal ECG at baseline though the PR interval may be up to 220 ms, the QRS interval up to 110 ms and the QTc interval up to 450 ms

Treatment and study plan

TD1414 2% cream

Drug

BID 7 days

Bactroban® (mupirocin) 2% cream

Drug

BID 7 days

Primary outcomes

  1. Participants With Clinical Cure According to Investigator's Assessment

    Time frame: At end of treatment (Day 8)

    At end of treatment (Day 8), the participants had their impetigo/Secondarily Infected Traumatic Lesions (SITL) evaluated by the (sub)investigator.

    Investigator's assessment of severity of infections (SIRS).

    • Exudates/pus
    • Crusting
    • Erythema
    • Oedema
    • Tissue Warmth
    • Itching
    • Pain

    Each sign/symptoms of infection was assessed by use of the following 4-point scale:

    • 0 = absent
    • 2 = mild
    • 4 = moderate
    • 6 = severe

    The scores were summed up to a total SIRS score.

    Clinical cure was either of the following:

    • Total absence of signs and symptoms of impetigo/SITL OR
    • Improvement - total SIRS score reduced to <8 and all individual clinical signs/symptoms included in the SIRS score should have been ≤4.

    Clinical failure was either of the following:

    • Signs and symptoms of impetigo/SITL that did not meet the definition of clinical cure
    • Unable to determine (e.g. participants who refuse clinical examination or did not show at end of treatment or follow-up).

Secondary outcomes

  1. Participants With Clinical Cure According to Investigator's Assessment

    Time frame: At follow up (Day 15)

    At follow up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.

  2. Participants With Clinical Cure According to Investigator's Assessment.

    Time frame: At end of treatment (Day 8) and follow-up (Day 15)

    At end of treatment (Day 8) and at follow-up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.

  3. Participants With Bacteriological Cure According to Bacteriological Samples

    Time frame: At end of treatment (Day 8), follow-up (Day 15) and end of treatment and follow-up

    At baseline (Day 1), end of treatment (EOT), and follow-up (FU), the investigator obtained a bacteriological sample to base the assessment on.

    Bacteriological cure was either of the following:

    • Eradication of the baseline pathogen.
    • Presumed eradication of the baseline pathogen
    • Infection with a pathogen different from the baseline pathogen at EOT or FU and the participant was NOT symptomatic.

    Bacteriological failure was any of the following:

    • Documented lack of eradication of the baseline pathogen.
    • Documented relapse (re-infection) with the baseline pathogen
    • Documented super-infection, i.e. infection with a pathogen different from the baseline pathogen at EOT or FU, and the participants was symptomatic
    • Presumed persistence of baseline pathogen: Non-evaluable participants- participants who refused bacteriological examination or did not show at EOT or FU, and clinical failures who had no bacteriological sample to rule out bacterial infection.

  4. Participants With Clinical and Bacteriological Cure According to Investigator's Assessment and Bacteriological Samples

    Time frame: At end of treatment (Day 8), follow-up (Day 15) and end of treatment and follow-up

    At end of treatment (Day 8) and at follow-up (Day 15) the participants had their impetigo/SITL evaluated by the (sub)investigator.

    At baseline (Day 1), end of treatment (Day 8) and at follow-up (Day 15) the investigator obtained a bacteriological sample on which an assessment of bacteriological cure was based.

  5. Participants With Clinical Cure According to Investigator's Assessment

    Time frame: At Day 4

    At Day 4 the participants had their impetigo/SITL evaluated by the (sub)investigator.

Sponsors and collaborators

Lead sponsor

LEO Pharma

Industry

Registry information

Official study title

Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Feb 29, 2008
Registry last updated
Mar 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.